Home » BioMarin Initiates Phase I Trial for BMN 673 in Patients With Advanced Hematological Malignancies

BioMarin Initiates Phase I Trial for BMN 673 in Patients With Advanced Hematological Malignancies

July 15, 2011

BioMarin Pharmaceutical announced the initiation of a Phase I trial for BMN 673, a poly ADP-ribose polymerase (PARP) inhibitor, for the treatment of patients with advanced hematological malignancies.
MarketWatch

10Mar
FDA Drug GMP Facility Inspections During the Pandemic
16Mar
Pharmaceutical Naming Regulation: Understanding the Latest Developments
18Mar
Pharmaceutical Postmarket Surveillance: Latest Developments in the Era of COVID-19
23Mar
Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges
30Mar
Data Integrity for GMP/Postmarket Professionals: Core Requirements, Expectations and Challenges
06Apr
Medical Device Cybersecurity: Understand the Latest Developments

BioMarin Initiates Phase I Trial for BMN 673 in Patients With Advanced Hematological Malignancies

Upcoming Events

FDA Drug GMP Facility Inspections During the Pandemic

Pharmaceutical Naming Regulation: Understanding the Latest Developments

Pharmaceutical Postmarket Surveillance: Latest Developments in the Era of COVID-19

Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

Data Integrity for GMP/Postmarket Professionals: Core Requirements, Expectations and Challenges

Medical Device Cybersecurity: Understand the Latest Developments

Featured Products

Biological Risk Evaluation and Management for Medical Devices

GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

President Biden Issues Executive Order on U.S. Supply Chain

Priority Healthcare Settles Diabetes Test Lawsuit with Roche for $43 Million

Pfizer/BioNTech Vaccine Equally Effective for All Age Groups, Israeli Study Says

Siemens Healthineers’ COVID-19 Antigen Lab Test Receives CE Mark

The Revised ICH E8: A Guide to New Clinical Trial Requirements